This site is intended for healthcare professionals
News

Canaglu approved by MHLW (Japan) for treatment of chronic kidney disease complicated by type 2 diabetes. - Mitsubishi Tanabe

Read time: 1 mins
Published:26th Jun 2022

Mitsubishi Tanabe Pharma Corporation has approval for partial changes to Canaglu (canagliflozin) tablets 100 mg for the additional indication of chronic kidney disease complicated with type 2 diabetes mellitus ( excluding patients with end stage renal disease) or undergoing dialysis.

 

Type 2 diabetes mellitus is a major risk factor for the development and progression of chronic kidney disease (CKD)and CKD complicated with type 2 diabetes is very common.in such patients renal function decreases as the disease progresses but if renal failure develops., dialysis needs to be started. Dialysis not only reduces a patients quality of life but also is an important issue from the viewpoint of health economics. The approval of Canaglu will provide one option to resolve these issues and contribute to the quality of life.

Condition: Diabetes Type 2 and Kidney Disease
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.